Terapia gênica do glioblastoma multiforme
Resumo
Palavras-chave
Referências
Schneider T, Mawrin C, Scherlach C, Skalej M, Firsching R. Gliomas in adults. Dtsch Arztebl Int.201; 107(45):799-807.
Loew S, Schmidt U, Unterberg A, Halatsch ME. The epidermal growth factor receptor as a therapeutic target in glioblastoma multiforme and other malignant neoplasms. Anticancer Agents Med Chem. 2009;9:703-15.
Trindade V, Picarelli H, Figueredo E, Teixeira M. Gliomas: marcadores tumorais e prognóstico.
Dolecek TA, Propp JM, Stroup NE, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro Oncol 2012;14(Suppl5): v1-v49.
Loew S, Schmidt U, Unterberg A, Halatsch ME. The epidermal growth factor receptor as a therapeutic target in glioblastoma multiforme and other malignant neoplasms. Anticancer Agents Med Chem. 2009; 9:703-15.
Rossi M, Magnoli L, Miracco C, Mori E, Tosi P, Pirtoli L, et al. β-catenin and G|i1 are prognostic makers in glioblastoma. Cancer Bio| Ther.2011;11(8):753-61.
Osborne RH, Houben MP, Tijssen CC, Coebergh JW, Van CM. The genetic epidemiology of glioma. Neurology. v. 27. p. 1751- 5, 2001.
Dresemann G. Temozolomide in malignant glioma. Onco Targets Ther. v. 3. p.139– 146, 2010.
Ohka F, Natsume A, Wakabayashi, T. Current Trends in Targeted Therapies for Glioblastoma Multiforme. Neurology Research International v. 3. p. 124-137, 2012.
Mrugala M M. Advances and Challenges in the Treatment of Glioblastoma: A Clinician’s Perspective. Discov Med v.15. p.221-230, 2013.
Ohgaki H, kleihues P. Epidemiology and etiology of gliomas. ActaNeuropathol. v. 109. p. 93–108, 2005.
Holland EC. Curr. Opin. Neurol. 2011. Padros MD, Russo C. Chemotherapy of brain tumors. Semin. Surg. Oncol. v. 14. p. 88-95, 1998.
Sathomsumete S, Reardon DA, Desjardins A, Quinn JA, Vredenbrugh JJ, RICH JN. Molecularly targeted therapy for magnant glioma. Cancer. v. 110. p. 13-24, 2007.
Kesari S. Understanding glioblastoma tumor biology: the potential to improve current diagnosis and treatment. Semin Oncol. V. 38. P. 12-20, 2011.
Padros M. Temozolomide in combination with other cytotoxic agents. Semin. Oncol. v. 28. p. 24-33, 2001.
Ahmadloo N, Kani Aa, Mohammadianpanah M, Nasrolahi H, Omidvari S, Mosalaei A, Ansari M. Treatment outcome and prognostic factors of adult glioblastoma multiforme. J Egypt Natl Canc Inst.
v. 25. p. 21–30, 2013.
Von Deimling A, Korshunov A, Hartmann C, The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations. Brain Pathol. 2011.
Schold SC Jr, Kokkinakis DM, Chang SM, Berger MS, Hess KR, Schiff D, et al. O6- bencylguanine suppression of O6-alkylguanine-DNA alkyltransferase in anaplastic gliomas. Neuro Oncol. 2004.
Ducray F, Idbaih A, De Reynies A, Bieche I, Thillet J, Mokhtari K, et al.
Anaplasticoligodendrogliomas with 1p19q codeletion have a proneural gene expression profile, Mol Cancer. 2008.
Ducray F, Idbaih A, De Reynies A, Bieche I, Thillet J, Mokhtari K, et al. Anaplasticoligodendrogliomas with 1p19q codeletion have a proneural gene expression profile, Mol Cancer. 2008.
Apontamentos
- Não há apontamentos.